心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：海藻糖通过激活自噬保护心梗后的心脏

2018-05-08 MedSci MedSci原创

心血管自噬海藻糖心梗
关注

海藻糖（TRE）是一种由低等生物合成的非还原性二糖，其可以通过激活自噬来保护处于各种应激状态下的细胞。本研究的目的旨在评估TRE对慢性缺血性重塑模型小鼠的影响。本研究对野生型（WT）小鼠和beclin 1+/-转基因小鼠进行永久性左前降支（LAD）冠脉结扎，之后对其进行安慰剂或者TRE处理，4周后，通过超声心动图、组织学检测、重量检测、血液动力学检测和生化检测对小鼠进行评估。分析结果显示，与接受安

海藻糖（TRE）是一种由低等生物合成的非还原性二糖，其可以通过激活自噬来保护处于各种应激状态下的细胞。本研究的目的旨在评估TRE对慢性缺血性重塑模型小鼠的影响。

本研究对野生型（WT）小鼠和beclin 1+/-转基因小鼠进行永久性左前降支（LAD）冠脉结扎，之后对其进行安慰剂或者TRE处理，4周后，通过超声心动图、组织学检测、重量检测、血液动力学检测和生化检测对小鼠进行评估。分析结果显示，与接受安慰剂小鼠相比，TRE处理组小鼠的左室膨大程度更低，左室功能更佳。TRE可以增加心梗后4周心脏LC3-II的水平，提示其可以在体内激活心脏的自噬水平。此外，在TRE处理组的小鼠中，WT的左室功能、肺充血、心肌重塑、凋亡和纤维化的改善在beclin 1+/-小鼠中均明显受限，提示TRE是通过激活自噬水平起到心脏保护作用的。

研究结果显示，海藻糖可以通过激活自噬对心梗后的心脏起到保护作用。


原始出处：

本文系梅斯医学(MedSci)原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854025, encodeId=8d57185402580, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 28 20:45:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053413, encodeId=3610205341303, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Jan 22 08:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325826, encodeId=e4de13258267c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483908, encodeId=95fb1483908f2, content=<a href='/topic/show?id=0c75656e370' target=_blank style='color:#2F92EE;'>#海藻糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65673, encryptionId=0c75656e370, topicName=海藻糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=372e7924972, createdName=12498cb5m15暂无昵称, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313156, encodeId=446631315679, content=感觉保健品又找到了商机, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue May 08 09:51:05 CST 2018, time=2018-05-08, status=1, ipAttribution=)]
    2019-01-28 hbwxf

    #JACC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1854025, encodeId=8d57185402580, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 28 20:45:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053413, encodeId=3610205341303, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Jan 22 08:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325826, encodeId=e4de13258267c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483908, encodeId=95fb1483908f2, content=<a href='/topic/show?id=0c75656e370' target=_blank style='color:#2F92EE;'>#海藻糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65673, encryptionId=0c75656e370, topicName=海藻糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=372e7924972, createdName=12498cb5m15暂无昵称, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313156, encodeId=446631315679, content=感觉保健品又找到了商机, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue May 08 09:51:05 CST 2018, time=2018-05-08, status=1, ipAttribution=)]
    2019-01-22 lfyang

    #心梗后#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1854025, encodeId=8d57185402580, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 28 20:45:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053413, encodeId=3610205341303, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Jan 22 08:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325826, encodeId=e4de13258267c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483908, encodeId=95fb1483908f2, content=<a href='/topic/show?id=0c75656e370' target=_blank style='color:#2F92EE;'>#海藻糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65673, encryptionId=0c75656e370, topicName=海藻糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=372e7924972, createdName=12498cb5m15暂无昵称, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313156, encodeId=446631315679, content=感觉保健品又找到了商机, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue May 08 09:51:05 CST 2018, time=2018-05-08, status=1, ipAttribution=)]
    2018-05-10 一叶知秋

    #ACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1854025, encodeId=8d57185402580, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 28 20:45:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053413, encodeId=3610205341303, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Jan 22 08:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325826, encodeId=e4de13258267c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483908, encodeId=95fb1483908f2, content=<a href='/topic/show?id=0c75656e370' target=_blank style='color:#2F92EE;'>#海藻糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65673, encryptionId=0c75656e370, topicName=海藻糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=372e7924972, createdName=12498cb5m15暂无昵称, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313156, encodeId=446631315679, content=感觉保健品又找到了商机, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue May 08 09:51:05 CST 2018, time=2018-05-08, status=1, ipAttribution=)]
    2018-05-10 12498cb5m15暂无昵称

    #海藻糖#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1854025, encodeId=8d57185402580, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 28 20:45:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053413, encodeId=3610205341303, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Jan 22 08:45:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325826, encodeId=e4de13258267c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483908, encodeId=95fb1483908f2, content=<a href='/topic/show?id=0c75656e370' target=_blank style='color:#2F92EE;'>#海藻糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65673, encryptionId=0c75656e370, topicName=海藻糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=372e7924972, createdName=12498cb5m15暂无昵称, createdTime=Thu May 10 00:45:00 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313156, encodeId=446631315679, content=感觉保健品又找到了商机, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue May 08 09:51:05 CST 2018, time=2018-05-08, status=1, ipAttribution=)]
    2018-05-08 smartxiuxiu

    感觉保健品又找到了商机

    0

相关资讯

盘点：JACC5月第1期研究一览

1. 二尖瓣环钙化患者经导管二尖瓣置换术的预后研究DOI: 10.1016/j.jacc.2018.02.054对于严重的二尖瓣环钙化（MAC）病人，外科的二尖瓣置换术的风险较高，目前在世界范围内，有数例MAC患者成功接受了经导管二尖瓣置换术（TMVR），并建立了MAC患者的TMVR注册中心。本研究共纳入了106名接受有TMVR的MAC患者，患者的平均年龄为73 ± 12岁，女性占68%，平均

JACC：药物洗脱支架在大隐静脉损伤患者中远期疗效无优势

在ISAR-CABG临床试验中，接受药物洗脱支架（DES）治疗的大隐静脉移植物损伤患者的1年预后优于裸金属支架。本研究的目的旨在评估两个治疗组之间术后5年的预后差异。本研究将大隐静脉移植物损伤患者随机1：1分成DES组和裸金属支架组，主要终点事件是死亡、心梗或靶损伤血管再生（TLR）的组合事件。最终共纳入了610名患者，其中303名接受了DES治疗，307名接受了裸金属支架治疗。5年后，主要终点事

JACC：先心病患儿的大脑白质损伤可引起神经发育落后

在严重的先天性心脏病新生儿中，有60%患者被报道存在大脑损伤（BI），表现为大脑白质损伤或卒中。这些患者中也被报道过存在神经系统发育（ND）损伤，本研究的目的旨在评估单心室循环（SVP）和D-大动脉转位（d-TGA）新生儿的围手术期大脑损伤与神经系统发育情况的关系。本研究共纳入SVP和d-TGA的足月产婴儿，对其术前和术后进行大脑磁共振检查，并在12个月和30个月大时对患者的ND进行评估。最终，共

JACC：心肌应变性在心衰病人预后价值方面优于射血分数

目前，心衰的分级是根据患者的左室射血分数（LVEF）而定的，但其预后价值仍存在争议。心肌顺应性是独立于LVEF的一个心衰预后因素。本研究的目的旨在评估整体纵向应变（GLS）对心衰病人的预后价值。本研究纳入了4172名心衰病人，根据LVEF将其分成了LVEF减少组（LVEF <40%）、LVEF中等组（LVEF 40%-49%）和保留型LVEF组（LVEF ≥50%）；同时，根据患者的GLS，

Heart：抗凝治疗可明显改善TAVR术后患者预后

本研究的目的旨在评估抗凝药物对经导管主动脉瓣置换术（TAVR）后患者 跨瓣压差的影响和瓣膜血流动力学恶化（VHD）的发生率。本次多中心临床研究纳入了2466例TAVR术后的患者（平均年龄81±7岁，男性占46%），并在术后12个月对所有患者进行了超声心动图检查。其中有707例（28.7%）患者术后接受了抗凝药物的治疗（AC组），663例患者接受的是维生素K拮抗剂治疗，44例患者接受的是直接口服抗凝

Am J Cardiol：儿童胖乎乎的小手还与心脏健康有关？

根据美国心脏病杂志上发表的一项研究，肥胖儿童的手腕周长与左心室的大小、质量均相关，其或可作为评估心血管疾病的风险的指标。